Patients with T2DM and proven cardiovascular disease have elevated markers of inflammation and endothelial stress, according to a new study.
Reference: Shore AC, Colhoun HM, Natali A, et al.Â Use of vascular assessments and novel biomarkers to predict cardiovascular events in type 2 diabetes: The SUMMIT VIP study. Diabetes Care. 2018.
Angela Shore, PhD, and colleagues at multiple European centers have found that patients with type 2 diabetes mellitus (T2DM) and proven cardiovascular disease (CVD) demonstrate elevated markers of inflammation and endothelial stress. Click through the slides above for details on their study and take home points for physicians.
Diabetes and Cardiovascular Disease. The European Innovative Medicine Initiative project SUMMIT was started in 2009 to identify novel markers for the prediction of CV complications in diabetes. Authors of this new study evaluated the ability of a panel of noninvasive vascular imaging, functional vascular tests, and emerging biomarkers to predict CV risk in T2DM patients.
The Study. Authors of the study examined a cohort within the SUMMIT study that included 458 subjects with T2DM and CVD and 527 subjects with T2DM, but no CVD. Carotid IMT and plaque area were used as vascular imaging modalities and plasma levels of biomarkers reflecting inflammation were collected. Also, CV events were monitored during a 3-year follow-up period.
Take Home Points: